Copyright
©The Author(s) 2022.
World J Gastroenterol. Dec 28, 2022; 28(48): 6791-6810
Published online Dec 28, 2022. doi: 10.3748/wjg.v28.i48.6791
Published online Dec 28, 2022. doi: 10.3748/wjg.v28.i48.6791
Table 1 Summary of coronavirus disease 2019 vaccines
| Corporation | Vaccine | Mechanism | Vaccination Group: Number of cases/number of vaccinations (%) | Invaccination Group: Number of cases/number of vaccinations (%) | Efficacy % (95%CI) |
| Pfizer-BioNTech[18] | BNT162b2 | mRNA | 8/21720 (0.037) | 162/21728 (0.746) | 95.0 (90.3-97.6) |
| Moderna[20] | mRNA-1273 | mRNA | 11/15210 (0.072) | 185/15210 (1.216) | 94.1 (89.3-96.8) |
| Oxford-AstraZeneca[25] | ChAdOx1 nCoV-19 (AZD122) | Vector | 27/4440 (0.608) | 71/4455 (1.594) | 62.1 (41.0-75.7) |
| Johnson & Johnson[26] | Ad26.COV2.S | Vector | 433/19113 (2.265) | 883/18924 (4.666) | 52.9 (47.1-58.1) |
| Sinovac Life Science[29] | Corona Vac | Inacctivated | 9/6559 (0.137) | 32/3470 (0.922) | 83.5 (65.4–92.1) |
- Citation: Ozaka S, Kobayashi T, Mizukami K, Murakami K. COVID-19 vaccination and liver disease. World J Gastroenterol 2022; 28(48): 6791-6810
- URL: https://www.wjgnet.com/1007-9327/full/v28/i48/6791.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i48.6791